Agilent Technologies Inc. (NYSE: A) was honored with the Asia Pacific Bioprocessing Excellence Award (ABEA 2023) under the Best Bioprocessing Supplier Award in the Analytical Services category. The awards ceremony was held in conjunction with the 10th annual Biologics Manufacturing Asia 2023 conference in Singapore.
Agilent has seen rapid growth in the bioprocessing space through acquisitions of ProZyme, Advanced Analytical Technologies, and e-MSion to bolster its portfolio with biopharma consumables, separators and mass spectrometer devices. The company’s high-performance liquid chromatography (HPLC) instruments increase accuracy, speed and performance for biotherapeutic and environmental research development.
In Singapore, Agilent collaborates with the Institute of Bioengineering & Bioimaging (IBB), a research institute of Singapore’s Agency for Science, Technology and Research (A*STAR), on new analytical approaches to the efficient translation of mRNA and lipid nanoparticles to improve manufacturing, storage and analytical techniques for mRNA vaccines.
“At Agilent, we pride ourselves on our bioprocessing excellence and expertise, especially in providing researchers with optimizing options to push scientific discoveries,” said Chow Woai Sheng, Singapore general manager and vice president of global instrument manufacturing of Agilent. “To be recognized by the life science community in Asia as the best bioprocessing supplier reflects our commitment to continue delivering high-quality answers in areas of unmet need and improving the quality of life locally and regionally.”
Agilent Singapore was established as its Asia Pacific Regional Center with a 172,000 square foot facility located in Yishun. In 2017, the company announced an SG$85 million investment plan in Singapore comprising manufacturing and research activities to expand over five years. Its Global Solution Development Center was launched a year later to develop integrated end-to-end workflow methods and novel applications for global markets.